Activin A Secreted by Cancer-Associated Fibroblasts Reduces the Sensitivity of Breast Cancer Cells to Ixazomib via Inhibition of Proteasome Activity
Biomolecules · 2025
DOI: 10.3390/biom15091318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Shuaiming Geng und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Northwest University, Xi'an 710069, China. Hauptthemen laut MEDLINE: Boron Compounds, Glycine, Breast Neoplasms, Cancer-Associated Fibroblasts. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ming-qing Gao, Yong Meng, Research start-up foundation in Northwest University.
Abstract (Originalsprache)
Breast cancer (BC) remains a leading cause of cancer-related mortality among women globally, and the role of cancer-associated fibroblasts (CAFs) in promoting BC progression is well established. Ixazomib, a proteasome inhibitor approved for the treatment of multiple myeloma, has demonstrated therapeutic potential in BC in preclinical trials. However, whether its efficacy is influenced by the tumor microenvironment, particularly CAFs, remains unclear. This study aims to investigate the role of CAFs with high expression of Activin A (encoded by INHBA) in modulating the sensitivity of BC cells to ixazomib. We demonstrate that ixazomib exhibited significant cytotoxicity in BC cells, but high-INHBA CAFs compromise ixazomib cytotoxicity through ERK-mediated proteasome suppression, reversible by Activin A antagonism. Additionally, the overexpression of INHBA in fibroblasts reduces the efficacy of ixazomib in xenograft models. Clinical data analysis revealed that high INHBA expression is associated with poor prognosis in BC patients and reduced immune cell infiltration. These findings suggest that targeting INHBA in CAFs could enhance the therapeutic efficacy of ixazomib in BC, particularly in patients with low INHBA expression. This study provides novel insights into the role of CAFs in drug resistance and identifies INHBA as a potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Northwest University, Xi'an 710069, China.
- College of Life Sciences, Northwest University, Xi'an 710069, China.
- Department of Oncology Surgery, Xi'an No. 3 Hospital-The Affiliated Hospital of Northwest University, Xi'an 710018, China.
ORCID-Profile: Yong Meng
Förderung
- Ming-qing Gao
- Yong Meng
- Research start-up foundation in Northwest University
- Cultivation Project for National Natural Science Foundation of Xi’an No. 3 Hospital, the Affiliated Hospital of Northwest University
Zitieren
APA
Geng, S., Liu, S., Liu, H., Wang, S., Niu, Y., Gao, J., Meng, Y., & Gao, M. (2025). Activin A Secreted by Cancer-Associated Fibroblasts Reduces the Sensitivity of Breast Cancer Cells to Ixazomib via Inhibition of Proteasome Activity. Biomolecules. https://doi.org/10.3390/biom15091318
Vancouver
Geng S, Liu S, Liu H, Wang S, Niu Y, Gao J, et al. Activin A Secreted by Cancer-Associated Fibroblasts Reduces the Sensitivity of Breast Cancer Cells to Ixazomib via Inhibition of Proteasome Activity. Biomolecules. 2025. doi:10.3390/biom15091318
BibTeX
@article{Geng2025,
author = {Geng, Shuaiming and Liu, Siyao and Liu, He and Wang, Siao and Niu, Yichen and Gao, Jing and Meng, Yong and Gao, Mingqing},
title = {Activin A Secreted by Cancer-Associated Fibroblasts Reduces the Sensitivity of Breast Cancer Cells to Ixazomib via Inhibition of Proteasome Activity},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15091318}
}
EUVIMED